Hubei Wushi Pharmaceutical Co. Ltd.

Primary study objectives: To evaluate the bioequivalence of the test preparation hydroxychloroquine sulfate tablets (provided by Hubei Wushi Pharmaceutical Research Institute Co., Ltd.) 0.2g and the reference preparation hydroxychloroquine sulfate tablets (Plaquenil®, produced by Sanofi-Aventis SA) 0.2g in healthy Chinese subjects under fasting and postprandial administration conditions. Secondary study objectives: To observe the safety of the test preparation and the reference preparation in healthy subjects.

Pharmacokinetic parameters were used as the primary endpoints to compare the pharmacokinetic behaviors of the test preparation, valsartan amlodipine tablets (I) provided by Hubei Wushi Pharmaceutical Co., Ltd., and the reference preparation, valsartan amlodipine tablets (I) (Beijing Novatis Pharmaceuticals Co., Ltd., trade name: Beibote®) in healthy subjects after oral administration in the fasting/postprandial state, and to evaluate the bioequivalence of the two preparations.

Main research purpose: Using Ezetimibe Atorvastatin Calcium Tablets (II) (Specification: 10 mg/20 mg) developed by Hubei Wushi Pharmaceutical Co., Ltd. as the test preparation and Ezetimibe Atorvastatin Calcium Tablets (trade name: Atozet®, specification: 10 mg/20 mg) produced by Merck Sharp & Dohme B.V. as the reference preparation, the pharmacokinetic parameters of the test preparation and the reference preparation in healthy subjects under fasting and postprandial conditions were investigated to evaluate the bioequivalence of the two preparations. Secondary research purpose: Observe the safety of the test preparation and the reference preparation in healthy subjects.